吉西他滨联合多西他赛治疗复发性卵巢癌完全缓解2例

[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].

作者信息

Ito Kimihiko, Adachi Susumu, Iijima Takashi, Nakatsuji Yuki, Kimura Toshio, Nobunaga Toshikatu

机构信息

Dept. of Obstetrics and Gynecology, Kansai Rosai Hospital.

出版信息

Gan To Kagaku Ryoho. 2003 Jan;30(1):141-4.

PMID:12557720

Abstract

The established standard treatment for advanced ovarian cancer is carboplatin and paclitaxel. However, more than 70% of patients have recurrent disease. The standard therapy for recurrent ovarian cancer has not been confirmed. It was reported that docetaxel had a 30-40% of response rate in patients with recurrent ovarian cancer, and that gemcitabine had a 13-22% response rate. The combination chemotherapy of gemcitabine and docetaxel is also applied to non-small cell lung cancer. We use a regimen of 800 mg/m2 of gemcitabine on day 1 and day 8 in combination with 70 mg/m2 of docetaxel on day 8 with a 3-week interval. We treated 2 patients with recurrent ovarian cancer who responded completely to combination chemotherapy with gemcitabine and docetaxel.

摘要

晚期卵巢癌既定的标准治疗方案是卡铂和紫杉醇。然而，超过70%的患者会出现疾病复发。复发性卵巢癌的标准治疗方法尚未得到证实。据报道，多西他赛对复发性卵巢癌患者的缓解率为30%-40%，吉西他滨的缓解率为13%-22%。吉西他滨和多西他赛的联合化疗也应用于非小细胞肺癌。我们采用的方案是在第1天和第8天使用800mg/m²的吉西他滨，并在第8天联合使用70mg/m²的多西他赛，每3周为一个周期。我们治疗了2例复发性卵巢癌患者，她们对吉西他滨和多西他赛联合化疗完全缓解。